MedTrace Logo

Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2

NCT05745467 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-11-18

No results posted yet for this study

Summary

The primary aim is to test whether preoperative asepsis with 5% nasal povidone iodine versus no preoperative asepsis with 5% nasal povidone iodine reduces proximal and distal SARS-CoV-2 transmission in operating rooms among patients who are acutely infected with SARS-CoV-2. The secondary aim is to test viral infectivity.

Conditions

  • SARS-CoV-2 Acute Respiratory Disease

Interventions

DRUG

Povidone Iodine 5% Soln,Top,Kit

5% povidone iodine will be swabbed in patients nares of the experimental group.

Sponsors & Collaborators

  • 3M

    collaborator INDUSTRY

  • University of Iowa

    lead OTHER

Principal Investigators

  • Randy W Loftus, MD · University of Iowa

  • Stephanie N Gibbons, BS · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
105 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-03
Primary Completion
2025-07-01
Completion
2026-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05745467 on ClinicalTrials.gov